Matches in Nanopublications for { ?s ?p "[WIN-R was an investigator-initiated trial in which patients with CHC received pegylated interferon ?-2b (1.5 ?g/kg/wk) plus a fixed ribavirin dose (800 mg/d) or a weight-based ribavirin dose (800 to 1400 mg/d) for 24 or 48 weeks.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 3 of
3
with 100 items per page.
- assertion description "[WIN-R was an investigator-initiated trial in which patients with CHC received pegylated interferon ?-2b (1.5 ?g/kg/wk) plus a fixed ribavirin dose (800 mg/d) or a weight-based ribavirin dose (800 to 1400 mg/d) for 24 or 48 weeks.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[WIN-R was an investigator-initiated trial in which patients with CHC received pegylated interferon ?-2b (1.5 ?g/kg/wk) plus a fixed ribavirin dose (800 mg/d) or a weight-based ribavirin dose (800 to 1400 mg/d) for 24 or 48 weeks.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP916565.RAcKbz-bHCbGEYYKwGVjxvgila61nfg3nx9epn1zEf0Ws130_assertion description "[WIN-R was an investigator-initiated trial in which patients with CHC received pegylated interferon ?-2b (1.5 ?g/kg/wk) plus a fixed ribavirin dose (800 mg/d) or a weight-based ribavirin dose (800 to 1400 mg/d) for 24 or 48 weeks.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP916565.RAcKbz-bHCbGEYYKwGVjxvgila61nfg3nx9epn1zEf0Ws130_provenance.